Sino Biopharmaceutical’s M701 CD3/EpCAM Bispecific Antibody NDA Accepted in China for Malignant Ascites and Pleural Effusion Treatment 12
Sino Biopharmaceutical Receives Acceptance for M701 New Drug...
Sign in to continue:
Sino Biopharmaceutical Receives Acceptance for M701 New Drug...
Broker: CGS International Date of Report: May 7, 2026 Excer...
VTech Holdings Limited to Hold Board Meeting on 21 May 2026 ...
Kindstar Globalgene Technology, Inc. Discloseable Transactio...
SSY Group Limited: Key Product Development Update – Approval...
Uni-President China Holdings Ltd. Releases Q1 2026 Unaudited...